Concert Pharmaceuticals to Present at Three Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences:

• The Wells Fargo Securities 2015 Healthcare Conference on September 9, 2015 at 3:30 p.m. EDT in Boston, MA;
• The Baird 2015 Healthcare Conference on September 10, 2015 at 9:05 a.m. EDT in New York, NY; and
• The Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015 at 2:30 p.m. EDT in New York, NY.

A live webcast of Concert’s presentations at these conferences may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert’s website for 2 weeks following each presentation.

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The Company is developing a broad pipeline targeting CNS disorders, genetic diseases, renal disease, inflammatory diseases and cancer. For more information, please visit www.concertpharma.com.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150902005196/en/

Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284
Vice President, Corporate Communications and Investor Relations
[email protected]

Source: Concert Pharmaceuticals, Inc.

You May Also Be Interested In

• What The Washington Post and Mark Robichaux Got Wrong About Menhaden
• Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000
• First Horizon Leader Keva Latham Named to Super Women in Business Class of 2026